Positive recommendations from EMA's CHMP for Selincro, Adasuve and Perjeta

17 December 2012

Last week’s deliberations of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), announced on Friday, resulted in good news for Lundbeck (LUN: D), Alexza Pharmaceuticals (Nasdaq: ALXA) and Roche (ROG: SIX), but not for Genzyme and Isis Pharmaceuticals or Vanda(see separate story today).

First up, the (CHMP) has recommended granting a marketing authorisation for Danish drugmaker Lundbeck’s Selincro (nalmefene), a medicinal product intended for the reduction of alcohol consumption in adults with alcohol dependence.

Selincro is indicated to help lower alcohol consumption in adults with alcohol dependence who have a high drinking risk level (consumption of more than 60g of alcohol per day for males, and more than 40g of alcohol per day for females), who do not have physical withdrawal symptoms and who do not require immediate detoxification.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK